David Patterson

David Patterson

Auto-generated profile, based on publicly available information

David Patterson

Department of Biological Sciences and Eleanor Roosevelt Institute, University of Denver, 2199 S. University Blvd., Denver, CO 80208, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2009 in Human Genetics
Verified
Journal Article
Closed access
PDF file
DPDavid Patterson
David Patterson

10 January 2005 in Nature Reviews Genetics
Verified
Journal Article
Closed access
DPDavid Patterson
David Patterson
Alberto CostaAlberto Costa
Alberto Costa

1 January 2007 in Mental Retardation and Developmental Disabilities Research Reviews
Verified
Journal Article
Closed access
PDF file
DPDavid Patterson
David Patterson

16 March 2006 in Behavior Genetics
Verified
Journal Article
Closed access
PDF file
CBChristine Butler
Christine Butler
AKAaron J. Knox
Aaron J. Knox
JBJeffrey Bowersox
Jeffrey Bowersox
SFStacy Forbes
Stacy Forbes
DPDavid Patterson
David Patterson

12 December 2014 in Antioxidants
Verified
Journal Article
Open access
PDF file
ERErika Ross
Erika Ross
AWAimee Winter
Aimee Winter
HWHeather Wilkins
Heather Wilkins
WSWhitney A. Sumner
Whitney A. Sumner
NDNathan Duval
Nathan Duval
Daniel LinsemanDaniel Linseman
Daniel Linseman
Depletion of the endogenous antioxidant, glutathione (GSH), underlies progression of the devastating neurodegenerative disease, amyotrophic lateral sclerosis (ALS). Thus, strategies aimed at elevating GSH may yield new therapeutics for ALS. Here, we investigated the effects of a unique non-denatured whey protein supplement, Immunocal®, in the transgenic Gly position 93 to Ala (G93A) mutant hSOD1 (hSOD1G93A) mouse model of ALS. Immunocal® is rich in the GSH precursor, cystine, and is therefore capable of bolstering GSH content. Transgenic hSOD1G93A mice receiving Immunocal® displayed a significant delay in disease onset compared to untreated hSOD1G93A controls. Additionally, Immunocal® treatment significantly decreased the rate of decline in grip strength and prevented disease-associated reductions in whole blood and spinal cord tissue GSH levels in end-stage hSOD1G93A mice. However, Immunocal® did not extend survival, likely due to its inability to preserve the mitochondrial GSH pool in spinal cord. Combination treatment with Immunocal® and the anti-glutamatergic compound, riluzole, delayed disease onset and extended survival in hSOD1G93A mice. These findings demonstrate that sustaining tissue GSH with Immunocal® only modestly delays disease onset and slows the loss of skeletal muscle strength in hSOD1G93A mice. Moreover, the inability of Immunocal® to rescue mitochondrial GSH in spinal cord provides a possible mechanism for its lack of effect on survival and is a limiting factor in the potential utility of this supplement as a therapeutic for ALS.

1 January 2009 in Gene
Verified
Journal Article
Closed access
AKAaron J. Knox
Aaron J. Knox
CGChristine Graham
Christine Graham
JBJohn Bleskan
John Bleskan
GBGary Brodsky
Gary Brodsky
DPDavid Patterson
David Patterson